Edgestream Partners, L.P. Editas Medicine, Inc. Transaction History

Edgestream Partners, L.P.

  • $2.23 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$7.03 - $11.53 $1.01 Million - $1.66 Million
-144,112 Reduced 48.21%
154,789 $1.12 Million
Q4 2022

Feb 13, 2023
BUY
$8.32 - $13.21 $699,695 - $1.11 Million
84,098 Added 39.15%
298,901 $2.65 Million
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $2.61 Million - $4.17 Million
214,803 New
214,803 $2.63 Million

Others Institutions Holding EDIT

# of Institutions
244
Shares Held
56.8M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $90M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Edgestream Partners, L.P. Portfolio

Follow Edgestream Partners, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Edgestream Partners, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Edgestream Partners, L.P. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email